Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Evotec Se (EVO)

Evotec Se (EVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,633,650
  • Shares Outstanding, K 354,371
  • Annual Sales, $ 845,740 K
  • Annual Income, $ -90,820 K
  • EBIT $ -175 M
  • EBITDA $ -74 M
  • 60-Month Beta 1.44
  • Price/Sales 1.97
  • Price/Cash Flow 170.11
  • Price/Book 1.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.06
  • Number of Estimates 2
  • High Estimate -0.04
  • Low Estimate -0.08
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.28 +9.78%
on 11/22/24
5.64 -16.67%
on 11/15/24
+0.57 (+13.80%)
since 11/08/24
3-Month
2.90 +62.07%
on 10/15/24
5.64 -16.67%
on 11/15/24
+1.36 (+40.72%)
since 09/09/24
52-Week
2.85 +64.91%
on 08/08/24
12.00 -60.83%
on 12/28/23
-5.02 (-51.65%)
since 12/08/23

Most Recent Stories

More News
Evotec Announces Change in Management Board

Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024

EVO : 4.70 (+1.95%)
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up

Halozyme Therapeutics, Inc. HALO announced that it has withdrawn its non-binding proposal to acquire Evotec SE EVO for €11.00 per share in cash. The acquisition offer implied a fully diluted equity value...

CSTL : 30.91 (-0.90%)
SPRO : 1.1400 (-2.56%)
HALO : 49.06 (+1.36%)
EVO : 4.70 (+1.95%)
Comment on Withdrawn Non-Binding Offer

HAMBURG, GERMANY / ACCESSWIRE / November 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480)(NASDAQ:EVO)

EVT : 25.22 (-0.36%)
EVO : 4.70 (+1.95%)
Just - Evotec Biologics Opens Cutting-Edge Biologics Facility - J.POD(R) Toulouse, France (EU)

J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region

EVT : 25.22 (-0.36%)
EVO : 4.70 (+1.95%)
Evotec SE Provides Guidance Update

HAMBURG, GERMANY / ACCESSWIRE / August 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it has refined its...

EVO : 4.70 (+1.95%)
RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced today that Leesa Gentry has joined the Company...

RNXT : 1.4300 (+2.14%)
EVO : 4.70 (+1.95%)
Stocks Climb Before the Open as Investors Weigh Economic Outlook, U.S. JOLTs Report in Focus

June S&P 500 futures (ESM23) are up +0.29%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.61% this morning after three major U.S. benchmark indices finished the regular session mixed as weaker-than-expected...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
TSLA : 389.79 (+0.15%)
VORB : 0.0769 (-34.83%)
OKYO.LN : 1.400 (-24.32%)
BFLY : 3.30 (+1.23%)
AMC : 4.51 (-4.65%)
ONCT : 0.5266 (-24.11%)
EVO : 4.70 (+1.95%)
HLN : 9.64 (-0.31%)
CRBG : 31.27 (-2.13%)
TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen

Toronto Innovation Acceleration Partners (“TIAP”) and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the two companies have expanded LAB150,...

EVO : 4.70 (+1.95%)
Adapsyn Bioscience enters into strategic collaboration with Evotec

/CNW/ - Adapsyn Bioscience Inc., a chemical bioinformatics company that discovers novel drug-like small molecules, today announced a strategic collaboration...

EVO : 4.70 (+1.95%)
Adapsyn Bioscience enters into strategic collaboration with Evotec

/PRNewswire/ - Adapsyn Bioscience Inc., a chemical bioinformatics company that discovers novel drug-like small molecules, today announced a strategic...

EVO : 4.70 (+1.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of...

See More

Key Turning Points

3rd Resistance Point 4.84
2nd Resistance Point 4.79
1st Resistance Point 4.74
Last Price 4.70
1st Support Level 4.64
2nd Support Level 4.59
3rd Support Level 4.54

See More

52-Week High 12.00
Fibonacci 61.8% 8.50
Fibonacci 50% 7.42
Fibonacci 38.2% 6.35
Last Price 4.70
52-Week Low 2.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar